A new study validates the Sybil AI model for predicting lung cancer risk using low-dose CT in a predominantly Black cohort at an urban safety-net hospital.
Key Details
- 1Study presented at the 2025 IASLC World Conference on Lung Cancer.
- 2Validation conducted at UI Health on 2,092 baseline low-dose CT scans from 2014-2024.
- 3Cohort primarily Non-Hispanic Black (62%), with 13% Hispanic and 4% Asian.
- 4Sybil demonstrated strong Area Under the Curve (AUC): 0.94 (1 yr), 0.90 (2 yr), 0.86 (3 yr), 0.85 (4 yr), 0.80 (5 yr), 0.79 (6 yr).
- 5Results remained strong after restricting to Black participants and excluding recent diagnoses.
- 6The Sybil Implementation Consortium will advance to prospective clinical trials for clinical workflow integration.
Why It Matters
Demonstrating reliable AI performance in racially and socioeconomically diverse settings is crucial for equitable lung cancer screening. This validation may facilitate broader adoption and help address longstanding disparities in lung cancer outcomes.
Source
EurekAlert
Related News
•EurekAlert
MSK Research: Proton Therapy, AI Pain Summaries, and Tumor Metastasis Insights
MSK Cancer Center research advances include proton therapy for leptomeningeal metastasis and evaluating large language models for cancer pain summary.
•EurekAlert
MD Anderson Highlights Imaging AI and Proton Therapy Trends Before 2025 ASTRO
MD Anderson experts discuss advances in imaging AI, biomarkers, and proton therapy ahead of the 2025 ASTRO meeting.
•EurekAlert
$16M PRISM Trial Launches to Evaluate AI in Breast Cancer Mammography
A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.